Taysha Gene Therapies, Inc.
NASDAQ:TSHA
2.15 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.112 | 3.411 | 3.604 | 4.746 | 2.395 | 4.706 | 2.502 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.3 | 0.325 | 0.366 | 0.331 | 0.703 | 0.631 | 1.679 | 0.3 | 0.3 | 0.257 | 0.209 | 0.166 | 0.085 | 0.032 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.812 | 3.086 | 3.238 | 4.415 | 1.692 | 4.075 | 0.823 | -0.3 | -0.3 | -0.257 | -0.209 | -0.166 | -0.085 | -0.032 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.73 | 0.905 | 0.898 | 0.93 | 0.706 | 0.866 | 0.329 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 15.073 | 20.657 | 12.682 | 11.791 | 19.791 | 12.514 | 13.861 | 16.391 | 23.118 | 37.799 | 37.918 | 39.528 | 30.643 | 23.854 | 12.26 | 11.057 | 3.062 | 5.514 | 0.987 |
| General & Administrative Expenses
| 7.338 | 7.084 | 6.719 | 8.589 | 5.988 | 8.751 | 7.341 | 8.683 | 9.867 | 11.469 | 11.806 | 11.153 | 10.129 | 8.236 | 6.107 | 3.984 | 0.948 | 0.07 | 0.128 |
| Selling & Marketing Expenses
| -0.3 | -0.325 | -0.366 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.038 | 6.759 | 6.353 | 8.589 | 5.988 | 8.751 | 7.341 | 8.683 | 9.867 | 11.469 | 11.806 | 11.153 | 10.129 | 8.236 | 6.107 | 3.984 | 0.948 | 0.07 | 0.128 |
| Other Expenses
| -1.237 | -1.058 | -1.561 | 0.616 | 0.003 | -0.008 | -0.006 | -0.001 | -0.003 | -0.008 | 0 | 0 | 0 | 0 | 17.03 | 0 | -17.21 | 0.18 | 0 |
| Operating Expenses
| 22.111 | 27.416 | 19.035 | 20.996 | 25.779 | 21.265 | 21.202 | 25.074 | 32.985 | 49.268 | 49.724 | 50.681 | 40.772 | 32.09 | 18.367 | 15.041 | 4.01 | 5.584 | 1.115 |
| Operating Income
| -21.299 | -24.33 | -15.797 | -16.25 | -23.384 | -16.559 | -55.12 | -25.074 | -32.985 | -49.268 | -49.724 | -50.681 | -40.772 | -32.09 | -18.367 | -15.041 | -4.01 | -5.584 | -1.115 |
| Operating Income Ratio
| -19.154 | -7.133 | -4.383 | -3.424 | -9.764 | -3.519 | -22.03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.371 | 0.269 | 63.538 | -100.837 | 0.003 | -1.063 | -0.603 | -1.233 | -0.888 | -0.843 | -0.691 | -0.506 | -0.154 | 0.066 | 0.049 | -0.001 | -17.21 | 0.18 | -1.115 |
| Income Before Tax
| -20.928 | -24.061 | 47.741 | -117.087 | -24.598 | -17.622 | -55.723 | -26.307 | -33.873 | -50.111 | -50.386 | -51.187 | -40.926 | -32.024 | -18.318 | -15.042 | -21.22 | -5.431 | -1.115 |
| Income Before Tax Ratio
| -18.82 | -7.054 | 13.247 | -24.671 | -10.271 | -3.745 | -22.271 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.282 | -3.549 | -0.331 | 1.443 | 2.437 | 2.334 | 1.233 | 0.888 | 0.843 | 0.691 | 0.037 | 0.04 | 0.066 | 0.049 | -0.003 | -21.22 | 0.027 | -1.161 |
| Net Income
| -20.928 | -24.061 | 47.741 | -117.087 | -24.598 | -20.059 | -58.057 | -27.54 | -34.761 | -50.954 | -50.386 | -51.187 | -40.926 | -32.024 | -18.318 | -15.042 | -21.22 | -5.431 | -1.115 |
| Net Income Ratio
| -18.82 | -7.054 | 13.247 | -24.671 | -10.271 | -4.262 | -23.204 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.09 | -0.1 | 0.26 | -0.93 | -0.38 | -0.32 | -1.03 | -0.67 | -0.87 | -1.33 | -1.32 | -1.35 | -1.09 | -0.87 | -1.04 | -1.28 | -0.61 | -0.36 | -0.074 |
| EPS Diluted
| -0.09 | -0.1 | 0.26 | -0.93 | -0.38 | -0.32 | -1.03 | -0.67 | -0.87 | -1.33 | -1.32 | -1.35 | -1.09 | -0.87 | -1.04 | -1.28 | -0.61 | -0.36 | -0.074 |
| EBITDA
| -20.999 | -24.005 | -15.431 | -16.25 | -22.815 | -15.917 | -18.507 | -24.789 | -32.687 | -49.005 | -49.695 | -50.478 | -40.647 | -31.992 | -18.312 | -15.041 | -21.22 | -5.404 | -1.115 |
| EBITDA Ratio
| -18.884 | -7.038 | -4.282 | -3.424 | -9.526 | -3.382 | -7.397 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |